Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study
Background Safinamide is a recent multimodal antiparkinsonian drug that inhibits monoamine oxidase B and modulates the glutamatergic system with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). This post-hoc analysis of the European SYNAPSES study provides first-time data on the use of safinamide in routine clinical practice in Belgium. Objective To describe the efficacy and safety of safinamide in Belgian PD patients in real-life conditions. Methods Post-hoc analysis of the Belgian cohort from the European SYNAPSES trial, which was an observational, multicenter, re... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
SPRINGER HEIDELBERG
|
Schlagwörter: | Parkinson's disease / Safinamide / MAO-B inhibitor / Real-life evaluation / Belgium / Fluctuation / Levodopa / Safety / Effectiveness |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26918243 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/1942/38847 |